Immune Stimulation With Recombinant Human Granulocyte Colony –Stimulating Factor for Coronavirus Disease 2019 (COVID-19)

The sobering mortality of coronavirus disease 2019 (COVID-19), the pandemic triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the few proven treatments have stimulated a global effort to rapidly discover and disseminate novel therapies. A noteworthy feature of the disease is the marked degree of lymphopenia in many hospitalized patients with COVID-19 and the association of lymphopenia with adverse outcomes.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research